Castle Creek Holdings to acquire Fibrocell Science Inc.and with it FCX 007 a proposed treatment for epidermolysis bullosa

Castle Creek Pharmaceutical Holdings, Inc. announced it has reached an agreement to acquire Fibrocell Science, Inc. a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases. With the resources of CCP Holdings’ subsidiary, Castle Creek Pharmaceuticals, LLC (“Castle Creek”), a privately held biopharmaceutical company developing innovative therapies for patients with rare, serious or debilitating dermatologic conditions, Fibrocell’s gene therapy platform can be advanced into additional areas of high, unmet need with the potential to develop multiple, promising new therapies.Both companies have advanced investigational therapies for the treatment of multiple types of EB (epidermolysis bullosa) into late-stage clinical research. Fibrocell’s lead gene therapy candidate, FCX 007, is being evaluated in a Phase III pivotal trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). In addition, Fibrocell is evaluating FCX 013 for the treatment of moderate to severe localized scleroderma in a Phase 1/II clinical trial. Castle Creek is committed to continuing that research and development. Castle Creek will also continue Phase IIb development of CCP 020 for epidermolysis bullosa simplex (EBS) and other forms of EB.